07:00 , Sep 24, 2012 |  BioCentury  |  Emerging Company Profile

Arcarios: Protecting chondrocytes

Current treatments for osteoarthritis treat the symptoms and relieve pain, but do not target the cause of the disease. Arcarios B.V. has established a preclinical pipeline of compounds to slow or prevent progression of bone...
08:00 , Dec 12, 2011 |  BC Week In Review  |  Financial News

Arcarios completes venture financing

Arcarios B.V. , Rotterdam, the Netherlands   Business: Autoimmune, Musculoskeletal   Date completed: 12/8/11   Type: Venture financing   Raised: €1 million ($1.6 million)   Investor: Agentschap   Note: Arcarios raised €1 million ($1.6 million)...
07:00 , Sep 13, 2010 |  BC Week In Review  |  Financial News

Arcarios completes venture financing

Arcarios B.V. , Rotterdam, the Netherlands   Business: Autoimmune, Musculoskeletal   Date completed: 9/8/10   Type: Venture financing   Raised: €4.1 million ($5.3 million)   Investors: BioGeneration Ventures; TiGenix N.V. ; Erasmus MC Biomedical; Gemma...
07:00 , Aug 30, 2010 |  BC Week In Review  |  Company News

Therosteon B.V., TiGenix autoimmune, musculoskeletal news

TiGenix spun out its ChondroBoost screening technology into newco Arcarios B.V. (Rotterdam, Netherlands), which was merged with drug discovery company Therosteon. The newco will focus on developing products to treat bone and joint diseases. Catholic...